Ethosuximide

Anti-epileptic Agent — NERVOUS SYSTEM

Key facts

Ethosuximide is an ofp drug in the Anti-epileptic Agent class catalogued in DrugCentral. It was first approved by the FDA in 1960. DrugCentral lists 1 molecular target, including CACNA1G. Recorded indications include Absence seizure.

• Approval status: ofp (first approved 1960 by the FDA).
• Drug class: Anti-epileptic Agent.
• Molecular targets: CACNA1G (1 listed in DrugCentral).
• Indications: Absence seizure.
• ATC code: N03AD01 (Succinimide derivatives).
• Molecular formula: C7H11NO2; molecular weight 141.17 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Absence seizure

Contraindications (9)

• Acute intermittent porphyria
• Depressive disorder
• Disease of blood AND/OR blood-forming organ
• Disease of liver
• Kidney disease
• Mood swings
• Neutropenic disorder
• Suicidal thoughts
• Systemic lupus erythematosus

Mechanism & targets

• Established pharmacologic class: Anti-epileptic Agent

Molecular targets (1)

Target	Gene	Action	Activity
Voltage-dependent T-type calcium channel subunit alpha-1G	CACNA1G	blocker	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1960-11-02	FDA	—	PARKE DAVIS

ATC classification

ATC code	Therapeutic hierarchy
N03AD01	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Succinimide derivatives
N03AD51	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Succinimide derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	520.9
Multiple-drug resistance	410.9
Petit mal epilepsy	321.7
Generalised tonic-clonic seizure	313.4
Status epilepticus	303.1
Drug ineffective	291.2
Ataxia	221.8
Myoclonic epilepsy	183.4
Intellectual disability	160.6
Somnolence	137.8
Behaviour disorder	133.7
Developmental delay	129.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ethosuximide is on its molecule page.

• Molecular formula: C₇H₁₁NO₂
• Molecular weight: 141.17 g/mol
• CAS number: 77-67-8
• InChIKey: HAPOVYFOVVWLRS-UHFFFAOYSA-N
• PubChem CID: 3291

CCC1(C)CC(=O)NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ethosuximide used for?

DrugCentral lists the following indications for Ethosuximide: Absence seizure.

How does Ethosuximide work?

Its molecular targets in DrugCentral include CACNA1G (blocker).

When was Ethosuximide first approved?

Ethosuximide was first approved by the FDA in 1960.

What drug class does Ethosuximide belong to?

Ethosuximide is in the Anti-epileptic Agent class.

What is the chemical formula of Ethosuximide?

Ethosuximide has the molecular formula C7H11NO2 and a molecular weight of 141.17 g/mol.

Sources

• DrugCentral drug card 1087 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL696 — compound record and bioactivity
• PubChem CID 3291 — chemical identifiers
• DrugBank DB00593 — drug record
• FDA UNII 5SEH9X1D1D — substance identity
• DailyMed: FDA labels for Ethosuximide — current prescribing information (label search)
• UniProt O43497 (CACNA1G) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.